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Summary
The TARGIT-A trial found no significant difference between TARGIT-IORT and EBRT in terms of local recurrence of breast cancer or breast cancer survival. In this longitudinal single-site TARGIT-A sub-study, TARGIT-IORT had similar cosmetic outcomes to EBRT but better breast-related quality of life, as reported by patients. This was despite this analysis being limited to patients who had received TARGIT-IORT as a separate procedure by reopening the wound (post-pathology).
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Patients treated with TARGIT-IORT on the TARGIT-A trial have similar self-reported cosmetic outcome but better breast-related QOL outcomes than patients treated with EBRT. This important evidence can facilitate the treatment decision making process for patients who have early breast cancer suitable for breast conserving surgery and inform their clinicians.
Introduction
Whole breast external beam radiotherapy (EBRT) delivered in 15-35 daily fractions over 3-7 weeks is standard adjuvant treatment for women undergoing breast conserving surgery for early breast cancer 1, 2 . EBRT may require temporary relocation for women who are geographically isolated or unable to travel daily 3 . EBRT can have acute toxicities such as erythema, oedema, breast induration and skin breakdown 4 and long-term toxicities including local pain, fibrosis, telangiectasia and cosmetic changes 4, 5 . Around 1-2% may develop pneumonitis, pulmonary fibrosis, cardiotoxicity, osteoradionecrosis, or secondary malignancies 4, 6, 7 . Some women choose to forego radiotherapy due to the inconvenience or potential toxicities, either accepting increased recurrence risks or choosing mastectomy [8] [9] [10] .
Targeted Intra-Operative Radiotherapy (TARGIT-IORT) allows delivery of radiation directly to tissues at the site of the primary tumour in a single session at the time of wide local excision (WLE) or shortly afterwards. The TARGIT-A trial compared TARGIT-IORT to conventional EBRT. Five year results found TARGIT-IORT to be non-inferior to EBRT in terms of risk of local recurrence when delivered during WLE (pre-pathology) (non-inferiority could not be established for postpathology, but the difference was not statistically significant) and there was no difference in breastcancer survival 11 . Toxicities were low; TARGIT-IORT had significantly fewer skin toxicities (0.5% vs. 2%) but higher risk of post-operative seromas (2% vs. 0.8%) 12 . Cosmesis analysis utilising digital photographs showed better outcomes with TARGIT-IORT in the first year 13 .
TARGIT-IORT is now considered an acceptable treatment option in several countries with delivery during WLE (pre-pathology) being the preferred approach. Awareness of cosmesis and QOL outcomes is paramount when clinicians are discussing treatment options with patients, in particular when comparing treatments with similar efficacy and survival. This sub-study is the first comprehensive investigation of patient reported cosmesis and breast-related QOL outcomes comparing patients randomised to TARGIT-IORT vs. EBRT on the TARGIT-A trial.
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Patients and Methods
Patients and Treatment
Between 2000 and 2012 TARGIT-A registered 3451 patients from 33 centres in 11 countries.
Patients with early breast cancer suitable for breast conserving surgery were randomized to receive either a single dose of TARGIT-IORT (50kV X-rays with INTRABEAM (TM) Carl Zeiss, Oberkochen Germany) or conventional 3-7 weeks EBRT. TARGIT-IORT patients with unfavourable pathology also received EBRT in ~15% of cases however these were excluded from this analysis.
This sub-study includes 126 patients from three treatment centres in Western Australia. Relevant ethics approvals were obtained and all participants provided written informed consent.
TARGIT-IORT dose to 1cm was 5-6Gy (16-33Gy at applicator surface) and EBRT was conventional 3D conformal radiotherapy -(45-50.4Gy in 25-28 fractions).
Eligibility for Australian patients randomized to the post-pathology stratification was stricter than the main trial; unifocal invasive ductal (not lobular) <2cm tumours, node negative, hormone positive, limited DCIS and lymphovascular negative disease. Fourteen EBRT and 4 IORT patients in this analysis were randomised pre-pathology where these criteria did not apply hence some deviations are shown in Table 1 .
Instruments and evaluations
Patients were routinely assessed at baseline, i.e., after initial surgery, but before receiving either TARGIT-IORT (as a separate procedure) or EBRT, and annually thereafter for five years using the instruments given below:
The Global Harris Scoring System of Excellent, Good, Fair or Poor was used [14] [15] [16] . Responses are dichotomized into Excellent and Good (EG) or Fair and Poor (FP) categories (Table e1 www.redjournal.org). Harris Scores were also completed by a Radiation Oncologist, Nurse and an objective photographic measurement system (BCCT.core), however these data will be reported separately.
Quality of Life
The 
Panel Review of quality of life domains
To reduce multiple testing and investigate only relevant breast-related domains, we performed a hypothesis-generating panel review of the two breast-specific questionnaires (BR23 and BIABC).
The review was exploratory; we wished to hypothesise which domains might show differences between patients having TARGIT-IORT vs. EBRT. 
Analysis and Interpretation
Despite the panel review reducing the number of evaluable QOL domains from 26 to 8, a large number of tests were still required for the primary analysis. Statistical significance was therefore set at p<0.01 to account for multiple comparisons 22, 26 .
Clinical significance utilizing the Osoba method is discussed according to QOL reporting guidelines 22,27,28 . A difference of at least 10 points on a 100 point scale is considered a minimal clinically meaningful change; a difference between 10 and 20 points is considered a moderate effect; and differences over 20 are considered a large effect 22,29 .
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Sensitivity analyses were performed to investigate robustness of the complete case data. The EORTC scoring system allows domain scores to be calculated in two ways; a) only when all questions in that domain have been answered (complete case analysis) and b) when at least half of the questions in the domain have been answered, allowing the calculation of an average score for the domain (single imputation with mean substitution) 18 . Multiple imputation of missing data was also applied to both questionnaires 18,30-32 . Given the similarities in outcomes across the three datasets, only the findings from the complete case analysis are reported.
IBM-SPSS V22 (SPSS Inc,.Chicago, IL) was used for: scoring QOL questionnaires; non-parametric analysis (Mann-Whitney-U and Chi 2 ) of raw unadjusted data and for multiple imputation and single imputation for the sensitivity analyses. Generalized estimating equations (GEE) with a variable covariance structure were used for the longitudinal dichotomized cosmesis endpoint and linear mixed models were used for the continuous longitudinal QOL endpoints using SAS V9.3 (SAS Institute, Cary, NC).
Results
Of 385 Western Australian TARGIT-A patients, only the first 152 consecutive patients were invited to participate in this sub-study due to resource constraints, with 6 declining participation. A further 20 were excluded due to confounders which would render cosmesis data uninterpretable, including a) received both TARGIT-IORT and EBRT (n=9), b) received TARGIT-IORT during WLE (n=1), c) no radiotherapy given (n=2) or d) history of contralateral disease (n=8). This left 126 evaluable participants, of whom 60 had TARGIT-IORT and 66 had EBRT (Figure 1 ).
Participants and Compliance
Compliance was very good and nearly identical across both treatment groups however as expected in a longitudinal study, compliance decreased over time (Table e2 www.redjournal.org). Sensitive domains relating to sexual function had the worst compliance with a range of 21% to 81% missing M A N U S C R I P T
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Cosmesis
Despite a trend for greater proportions of TARGIT-IORT patients self-reporting an EG result compared to EBRT patients overall, multivariate longitudinal analysis did not reveal any statistically significant differences between treatment group at any time point (Figure 1 ). Models to test whether other factors (such as age, body mass index ,specimen size, EBRT boost and additional surgery) may have an impact revealed no other drivers of self-reported cosmetic outcome 33 .
Univariate analysis revealed TARGIT-IORT patients had better cosmetic outcome compared to EBRT patients at Year-5 with 90% and 68.4% scoring EG respectively (p=0.007) ( Figure 2 ).
Quality of life results
Mean baseline scores for the 8 QOL domains selected a-priori did not demonstrate any significant differences at the p<0.01 level between the two treatment groups (Table e3 www.redjournal.org).
Exploratory analysis of Global QOL scores showed significantly better scores for TARGIT-IORT patients at baseline (79.5 TARGIT-IORT, 70.3 EBRT p=0.007).
Beyond baseline, TARGIT-IORT patients tended to fare better than EBRT patients in terms of breast-related QOL. Non-parametric testing revealed statistically significantly better results consistently favoring the TARGIT-IORT group in the Arm Concerns domain at Year-1 (p<0.0001) (Table e4 www.redjournal.org), and Months 6 and 9 and Years 1, 3 and 4 (p<0.001) of the Breast Symptoms domain. A number of differences were also considered clinically significant (Table 2) .
Treatment (and its interaction with time) had a statistically and clinically significant impact on the Breast Symptoms (p=0.006) and Arm Concerns (p=0.005) domains, both favouring TARGIT-IORT (Table 3) . Age was also found to be a significant factor in the Body Image (p=0.004) and Sexual M A N U S C R I P T TARGIT-IORT patients scoring worse function from BL to 6 months, then better function from 9 months onwards with clinically significant differences at Years 1, 3 and 4. Age adjusted mean scores for QOL domains are illustrated in Figure 2 with further details shown in Table e5 www.redjournal.org.
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Although the core EORTC questionnaire was not used in the a-priori analysis, we explored the Global QOL domain, which contains two questions relating to overall health and overall quality of life respectively. A higher score denotes better global QOL and results revealed TARGIT-IORT patients consistently scored higher scores than EBRT patients with statistically significant differences found at baseline, 3 and 6 months and 1 year. Clinically significant differences were seen at 3 and 6 months (moderate and minimal clinical significance respectively) ( Figure e1 www.redjournal.org).
Sensitivity Analyses
All three approaches to analysis (complete case, single imputation, multiple imputation) produced similar parameter estimates and p-values. Minor disagreement was seen in two domains of the BIABC questionnaire at the p<0.05 level, but no differences were seen at the p<0.001 level.
Specimen size was significant (p=0.035) in the complete case analysis of body stigma but insignificant in the MI analysis (p=0.064). The treatment vs. time interaction of the arm concerns domain was significant for the complete case analysis (p=0.006) but insignificant in the MI analysis (p=0.112).
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The effect of missing data on the Year-5 cosmesis scores was tested by carrying forward the previous years' result. This increased the proportion of an EG score from 68.4% to 69% for the EBRT group and decreased the proportion from 90% to 88% in the TARGIT-IORT.
Discussion of results
Intra-operative radiotherapy is a new way to offer adjuvant breast radiotherapy and few studies of cosmesis and QOL have been reported [34] [35] [36] [37] . This TARGIT-A sub-study provides comprehensive patient-reported results comparing post-pathology TARGIT-IORT to EBRT. TARGIT-IORT was found to significantly impact breast symptoms, improving quality of life.
TARGIT-IORT patients tended to self-report better outcomes for both cosmesis and QOL, such that a higher number scored an EG cosmetic result across all time points, and they experienced fewer symptoms and better functioning in breast-related QOL.
The only significant difference in cosmesis was at Year-5 (EG scores were 68.4%-EBRT and 90%-TARGIT-IORT, p=0.007, which coincidentally were the lowest and highest scores reported by patients across all time points). Study attrition as a potential cause of this difference was ruled out by sensitivity analysis. Overall, the proportion of patients scoring themselves as EG was high, and compares well to previous research which has shown that 70-80% of EBRT patients can expect an EG cosmetic outcome 4 .
Clinically and statistically significant findings were seen at Year-1 for Arm Concerns and Month-6
for Breast Symptoms. At these time points, EBRT patients experienced moderately higher levels of treatment-related symptoms, including breast and arm pain, swelling, oversensitivity and skin problems. These findings are in keeping with the results obtained from cross-sectional studies of QOL in TARGIT-A patients in Germany (median follow-up 47 months; pre-pathology patients) 35, 37 and toxicity results from TARGIT-A 12 .
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The increase in self-reported breast symptoms in EBRT patients observed 6-months post-WLE which subsided by the 9 th month, was most likely because patients had only just finished their EBRT around this time, when waiting times were on average 4.5 months (2.3-7.9 months) for completion of EBRT. TARGIT-IORT patients had completed their treatment between 4 days and 4 months after WLE, with the average completion time of 1.6 months. Given the lack of significant difference between breast symptoms reported at 3-months, TARGIT-IORT patients had presumably recovered from their procedure by the time the 3-month questionnaire was administered, when EBRT patients were just starting radiotherapy. By 6-months, TARGIT-IORT patients had improved further in terms of breast side effects, but EBRT patients who had recently ceased or were still receiving treatment, were experiencing the peak of treatment-related side effects. By 9-months both treatment groups scored better than baseline scores, which is in keeping with other longitudinal
International QOL studies of EBRT 21,38 .
Breast symptoms for both groups continued to reduce over time, showing better results for both groups at 4 years (4.2 for TARGIT-IORT and 9.9 for EBRT) when compared to the German Cohort (8.6 for TARGIT-IORT and 19.2 for EBRT) 37 . A similar reduction in breast symptoms over time was also seen in the START-A and B trials which assessed breast symptoms for different regimens of EBRT from baseline to Year 5 and also QOL studies performed in Australia/New Zealand and Canada which assessed both short and long term QOL post EBRT 21,38,39 .
In comparison to the 50Gy EBRT arm of the START trials, patients treated with TARGIT-IORT in the present study reported fewer breast symptoms at months 6 and years 1 and 5, however the patients treated with EBRT in the present study showed worse breast symptoms across all follow-up time points compared to TARGIT-IORT 39,40 .
Overall, patients treated with TARGIT-IORT reported better global QOL scores at every time point.
Despite not reaching clinical significance, it is worth noting that TARGIT-IORT patients scored better global QOL at baseline (79.5) compared to the EBRT group (70.3, p=0.007) who had a M A N U S C R I P T
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Page 12 of 17 similar score to the baseline scores for the 50Gy EBRT group in the START trials (69.8) 40 . The administration of the baseline questionnaire in the present study was performed after patients were randomised. We may hypothesise that either patients randomised to the TARGIT-IORT arm were actually experiencing better QOL, or that simply being randomised to the single treatment may have had a positive effect on their sense of wellbeing which improved reported QOL. Anecdotally, patients randomised to TARGIT-IORT were visibly relieved to not have to endure the 6 week burden of EBRT, and patients randomised to EBRT would often become visibly upset when informed they drew the conventional arm (particularly those who would need to relocate to the city for the duration of their treatment, leaving behind dependents, animals, or other responsibilities).
Statistically and clinically significant differences seen between TARGIT-IORT and EBRT at 3 and 6 months suggests the impact of undergoing extended treatment was reflected in global QOL scores of EBRT patients. The administration of the 3-month BR23 generally coincided with the start of EBRT (the median time to start EBRT was 7.5 days prior to 3-month BR23). This may have contributed to the poorer global QOL scores in the EBRT group. Patients who received TARGIT-IORT completed the 3-month BR23 a median of 47 days after treatment, hence they may have returned to their usual routine by that time.
Sensitivity analyses comparing complete case, single imputation and multiple imputation datasets produced similar outcomes. This similarity can be explained by excellent completion rates and generally good health exhibited by participants which led to few occasions where imputation was required. Multiple imputation is complex and time consuming and is not necessary with the amount, type and pattern of missingness experienced by this dataset.
This analysis reports the experience of patients who received TARGIT-IORT as a separate procedure after WLE (post-pathology). Internationally, TARGIT-IORT during WLE (prepathology) is now the preferred approach and we would not anticipate that the concurrent procedure would result in worse cosmetic or QOL outcomes. As it is reasonable to expect that cosmetic outcome and quality of life would be worse in patients who have an additional procedure after M A N U S C R I P T
Page 13 of 17 WLE, this is a factor that would work against finding better outcomes with TARGIT-IORT vs.
EBRT in this study. Therefore, our findings of equal or better outcomes in such patients are even more significant.
Limitations and Strengths
This sub-study describes only a sub-set of TARGIT-A patients with a mix of patients from the pre and post-pathology stratifications. Sensitivity analysis showed missing data did not affect study outcomes, with the exception of sensitive questions relating to sexual function and intimacy in which missing data are universal 18,41 . On average, across each time point, 53% and 45% of TARGIT-IORT and EBRT patients respectively were sexually active, hence only half of the surveyed population could offer a score for the Sexual Enjoyment domain (on average 19 patients per group per time point). Such small numbers may reduce the generalisability of the reported findings for this domain despite excellent compliance rates. Furthermore, this study did not distinguish between partnered and non-partnered women, and information on adjuvant hormonal therapy was not reviewed, hence making it impossible to interpret whether a reduction in sexual function was potentially related to by these factors.
While the results of this study show TARGIT-IORT and EBRT patients have similar long-term outcomes, the main clinically significant differences were seen within the first year.. Collection of data at months 3, 6 and 9 post WLE which encompass the radiotherapy treatment time frame is therefore a strength of this study as other studies using a cross-sectional approach miss out on this valuable information. Consideration must be given to the timing of assessment to facilitate interpretation. In this study the significant date was WLE, however radiotherapy end date may have been easier to interpret. Arm Concerns 0.5 n/a n/a n/a 0.000** (12.7) 0.2 0.031* (7.5) 0.2 0.4 Body Concerns 1 n/a n/a n/a 0.9 0.7 0.9 0.4 0.9
Conclusion
Body Stigma 0.05 n/a n/a n/a 0.5 0.2 0.2 0.3 0.2 Transparency 0.5 n/a n/a n/a 0. Values in parentheses are the Osoba clinical significance score. Note that Osoba clinical significance is reached with a difference >10 on a 100 point scale. All clinically and statistically significant differences favoured TARGIT-IORT. 
